- Home
- STRO vs BMEA Comparison
STRO vs BMEA Comparison
Compare STRO & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- BMEA
- Stock Information
- Founded
- STRO 2003
- BMEA 2017
- Country
- STRO United States
- BMEA United States
- Employees
- STRO N/A
- BMEA N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- BMEA Health Care
- Exchange
- STRO Nasdaq
- BMEA Nasdaq
- Market Cap
- STRO 77.7M
- BMEA 65.8M
- IPO Year
- STRO 2018
- BMEA 2021
- Fundamental
- Price
- STRO $0.74
- BMEA $1.69
- Analyst Decision
- STRO Hold
- BMEA Strong Buy
- Analyst Count
- STRO 7
- BMEA 10
- Target Price
- STRO $3.97
- BMEA $22.30
- AVG Volume (30 Days)
- STRO 1.4M
- BMEA 2.2M
- Earning Date
- STRO 08-12-2025
- BMEA 07-30-2025
- Dividend Yield
- STRO N/A
- BMEA N/A
- EPS Growth
- STRO N/A
- BMEA N/A
- EPS
- STRO N/A
- BMEA N/A
- Revenue
- STRO $66,434,000.00
- BMEA N/A
- Revenue This Year
- STRO N/A
- BMEA N/A
- Revenue Next Year
- STRO N/A
- BMEA N/A
- P/E Ratio
- STRO N/A
- BMEA N/A
- Revenue Growth
- STRO N/A
- BMEA N/A
- 52 Week Low
- STRO $0.52
- BMEA $1.29
- 52 Week High
- STRO $5.17
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- STRO 42.62
- BMEA 43.22
- Support Level
- STRO $0.67
- BMEA $1.58
- Resistance Level
- STRO $0.79
- BMEA $3.08
- Average True Range (ATR)
- STRO 0.07
- BMEA 0.22
- MACD
- STRO -0.00
- BMEA -0.07
- Stochastic Oscillator
- STRO 26.22
- BMEA 7.33
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.